Amended Statement of Ownership (sc 13g/a)
February 13 2020 - 2:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of
1934
(Amendment No. 1)*
GENEREX
BIOTECHNOLOGY CORPORATION
(Name of Issuer)
Common stock, par value $.001
(Title of Class of Securities)
371485103
(CUSIP Number)
December 31, 2019
(Date of Event Which Requires Filing of
this Statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
¨
Rule 13d-1(b)
x Rule 13d-1(c)
¨
Rule 13d-l(d)
*The remainder of this cover
page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the
remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
|
CUSIP No. 371485103
|
AMENDMENT NO. 1 to SCHEDULE 13G
|
1. Names
of Reporting Persons.
Creek Mountain Partners, Inc.
2. Check the Appropriate Box if a Member of a Group
(See Instructions)
(a)
(b)
3. SEC Use Only
4. Citizenship or Place of Organization
Delaware
|
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With:
|
5. Sole Voting Power
|
|
|
|
796,447
shares of common stock, par value $.001
|
|
|
|
6. Shared Voting Power
|
|
|
|
7. Sole Dispositive Power
|
|
796,447
shares of common stock, par value $.001
|
|
8. Shared Dispositive Power
|
9. Aggregate Amount Beneficially Owned by Each Reporting
Person
796,447 shares of common
stock, par value $.001
10. Check if the Aggregate Amount in Row (9) Excludes
Certain Shares (See Instructions)
11. Percent of Class Represented by Amount in Row
(9)
1.66%
12. Type of Reporting Person (See Instructions)
CO
|
CUSIP No. 371485103
|
AMENDMENT NO. 1 to SCHEDULE 13G
|
Item 1.
GENEREX BIOTECHNOLOGY CORPORATION
|
|
(b)
|
Address of Issuer’s Principal Executive Offices
|
10102 USA Today Way, Miramar, Florida 33025
Item 2.
|
|
(a)
|
Name of Person Filing
|
Creek Mountain Partners, Inc.
|
|
(b)
|
Address of Principal Business Office or, if none, Residence
|
PO Box 1445
Exmore, Virginia 23350
Delaware
|
|
(d)
|
Title of Class of Securities
|
Common stock, par value $.001
371485103
Item 3. If this statement is filed pursuant to §§240.13d-1(b)
or 240.13d-2(b) or (c), check whether the person filing is a:
|
|
(a)
|
¨ Broker
or dealer registered under section 15 of the Act (15 U.S.C. 78o).
|
|
|
(b)
|
¨ Bank
as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
|
|
|
(c)
|
¨ Insurance
company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
|
|
|
(d)
|
¨ Investment
company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
|
|
|
(e)
|
¨ An
investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
|
|
|
(f)
|
¨ An
employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
|
|
|
(g)
|
¨ A
parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
|
|
|
(h)
|
¨ A
savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
|
|
(i)
|
¨ A
church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company
Act of 1940 (15 U.S.C. 80a-3);
|
|
|
(j)
|
¨ Group,
in accordance with §240.13d- I (b)(1)(ii)(J).
|
Item 4. Ownership.
Provide the following
information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
|
|
(a)
|
Amount beneficially owned: 796,447.
|
|
|
(b)
|
Percent of class: 1.66% *
|
|
|
(c)
|
Number of shares as to which the person has:
|
|
|
(i)
|
Sole power to vote or to direct the vote: 796,447.
|
|
|
(ii)
|
Shared power to vote or to direct the vote: _______.
|
|
|
(iii)
|
Sole power to dispose or to direct the disposition
of: 796,447.
|
|
|
(iv)
|
Shared power to dispose or to direct the disposition
of: _______.
|
* The percentage of the outstanding
common stock of the Issuer reported in this Item 4 is based on the assumption that there were 47,859,074 shares of common stock
of the Issuer outstanding as of December 31, 2019.
Item 5. Ownership of Five Percent or Less of a Class
If this statement is
being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following x.
Item 6. Ownership of More than Five Percent on Behalf of
Another Person.
N/A
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
N/A
Item 8. Identification and Classification of Members of the
Group
N/A
Item 9. Notice of Dissolution of Group
N/A
Item 10. Certification
By signing
below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
Date: February 11, 2020
|
CREEK MOUNTAIN PARTNERS, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ RONALD F. MATTHEWS, JR.
|
|
|
|
|
|
|
|
|
Name:
|
Ronald F. Matthews, Jr.
|
|
|
|
Title:
|
President
|
|
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Apr 2023 to Apr 2024
